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OBJECTIVES We studied enhancement of local gene delivery to the arterial wall by using an endovascular
catheter ultrasound (US).
BACKGROUND Ultrasound exposure is standard for enhancement of in vitro gene delivery. We postulate that
in vivo endovascular applications can be safely developed.
METHODS We used a rabbit model of arterial mechanical overdilation injury. After arterial overdilation,
US catheters were introduced in bilateral rabbit femoral arteries and perfused with plasmid-
or adenovirus-expressing blue fluorescent protein (BFP) or phosphate buffered saline. One
side received endovascular US (2 MHz, 50 W/cm2, 16 min), and the contralateral artery did
not.
RESULTS Relative to controls, US exposure enhanced BFP expression measured via fluorescence
12-fold for plasmid (1,502.1 6 927.3 vs. 18,053.9 6 11,612 mm2, p , 0.05) and 19-fold for
adenovirus (877.1 6 577.7 vs. 17,213.15 6 3,892 mm2, p , 0.05) while increasing cell death
for the adenovirus group only (26 6 5.78% vs. 13 6 2.55%, p , 0.012).
CONCLUSIONS Endovascular US enhanced vascular gene delivery and increased the efficiency of nonviral
platforms to levels previously attained only by adenoviral strategies. (J Am Coll Cardiol 2001;
37:1975–80) © 2001 by the American College of Cardiology
Cardiovascular diseases are by far the leading cause of death
in Western nations (1). Gene therapy to express specific
therapeutic factors was expected to revolutionize manage-
ment of these diseases. Unfortunately, this potential remains
unfulfilled largely because of problems with safety and
efficiency (2). In order to deliver genes to the cells, several
viral and nonviral vectors exist, with various idiosyncratic
advantages and limitations, but no current system achieves
all necessary requirements for practical application.
Adenovirus-mediated strategies, although highly efficient
(3), are limited at therapeutic doses by cytotoxicity, inflam-
matory infiltrate, phenotypic perturbation and transient
transgene expression (4) and, when applied clinically at
these doses, have even resulted in death. In contrast, direct
introduction of deoxyribonucleic acid (DNA) into the cell
using a plasmid is inefficient. After charge neutralization of
DNA, only 0.1% to 1% of target cells are transfected in vivo.
Even with the aid of transfection agents, these rates are
typically too low to achieve therapeutic effects in vivo (5,6).
Ultrasound permeabilizes cell membranes (7), and many
publications report in vitro US enhancement of transfection
using plasmids or liposomes with and without the addition
of stabilized gas bubbles (8–12). Investigators have demon-
strated that application of extracorporeal US can also alter in
vivo drug (13) or gene (14) delivery within constraints of US
penetration. However, these methods have yet to be suc-
cessfully applied to the leading cause of morbidity and
mortality.
Because restenosis represents an important clinical target
for vascular gene therapy, we hypothesized that catheter-
mediated endovascular ultrasound can enhance blue fluo-
rescent protein (BFP) gene delivery in a rabbit model of
arterial mechanical overdilation injury. Expression and dis-
tribution of BFP were assessed after angioplasty and
plasmid- or adenoviral-mediated gene delivery with or
without endovascular US. Specific histochemical studies of
local macrophage infiltrate, apoptosis and cell death were
also undertaken on treated artery segments to determine the
toxicity of this new adjunctive method.
METHODS
Vectors for gene delivery. A replication-deficient recom-
binant adenovirus-expressing BFP gene driven by a cyto-
megalovirus (CMV) promoter was constructed (Adv/
CMV-BFP) (Quantum Biotechnologies, Inc., Quebec,
Canada). The plasmid used for nonviral experiments ex-
pressed BFP gene under control of a CMV promoter
(p/CMV-BFP), obtained from Quantum Biotechnologies.
Ultrasound performance characteristics. The EKOS ul-
trasound catheter (EKOS Corp., Bothell, Washington) has
an outside diameter of 2.5 French, a central infusion lumen
of 180 mm and contains a cylindrical US transducer at the
tip that emits US energy in a radial pattern directed into the
artery wall. The US excitation signal used in the present
work was a 2 MHz sine wave in burst mode. A pulse
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repetition rate of 30 Hz was used with burst duration of
1.02 ms. The applied electrical power was adjusted to
achieve a target pulse average acoustic intensity of
50 W/cm2.
Surgical procedure. All animal experiments were per-
formed within institutional and National Institutes of
Health guidelines. New Zealand White male rabbits (three
per treatment) weighing 2.3 to 3.2 kg underwent general
anesthesia with isofluorane (3%) after induction with ket-
amine (35 mg/kg) and xylazine (6 mg/kg). Bilateral femoral
cutdowns were performed. Common femoral arteries were
exposed from inferior epigastric arteries to superficial fem-
oral arteries and isolated with atraumatic microclamps.
Superficial femoral arteries were cannulated. A 2 mm 3
2 cm Cordis SAVVY angioplasty balloon (Cordis Inc.,
Miami, Florida) was introduced and advanced to the prox-
imal clamp, inflated to 6 atm for two cycles of 1 min and
removed. The EKOS CT 2.5F US catheter was then
inserted. Through this catheter, arteries were infused with
150 ml of phosphate-buffered saline (PBS, control group),
150 ml of 1 3 109 pfu/ml Adv/CMV-BFP or 150 ml of
7.6 mg/ml p/CMV-BFP complexed with a 5:1 ratio of
Superfect (Qiagen, Valencia, California) and incubated
16 min each. During this period three arteries per treatment
group underwent intravascular US treatment, with con-
tralateral vessels treated using an identical control catheter
without activation of US. Saline irrigation was applied
perivascularly to maintain temperature below 34°C as mea-
sured by thermocouple in the US catheter.
Tissue harvesting and evaluation of delivery efficiencies.
Seven days after angioplasty and gene delivery, treated artery
segments were excised and divided into four equal portions.
One portion was snap frozen in mounting medium while
both remaining segments were fixed in 10% neutral buffered
formalin for 12 to 16 h. Formalin-fixed specimens were
paraffin-embedded and sectioned (5 mm) for evaluation of
BFP expression, macrophage infiltration and apoptosis as
described. Frozen specimens were sectioned for viability
study as described.
Evaluation of BFP expression. Efficiency of gene delivery
was assessed via BFP fluorescence as recorded on a Diag-
nostic Instruments SPOT digital camera from a Nikon
E600 epifluorescence microscope (Nikon Corporation, To-
kyo, Japan) with plan apochromat lenses using an FITC-
HYQ filter (EX 460-500, DM 505, BA 510–560). An
observer blind to conditions used an ImagePro Plus image
analysis suite to determine total BFP positive area in pixels.
Mean and standard error were tabulated for each treatment
with significance determined as described later.
Evaluation of local macrophage infiltrate. To visualize
presence of macrophages at the 7-day timepoint, three
sections per artery were incubated overnight at 37°C with a
primary monoclonal antibody to rabbit macrophage (clone
RAM-11; dilution 1:800; DAKO, Carpinteria, California).
Endogenous peroxidase activity was blocked with 3% H2O2
in methanol. Sections were incubated with peroxidase-
conjugated secondary antibody to mouse IgG (X56; dilution
1:100; Pharmingen, San Diego, California) and developed
in CN/DAB substrate (Pierce, Rockford, Illinois) to visu-
alize RAM-11 antigenic sites. An observer blind to condi-
tions tabulated number of RAM-11 positive cells per cross
section.
Evaluation of cellular viability. Frozen sections were
washed with saline, incubated with 0.4% trypan blue for
2 min, then allowed to stand in saline for 5 min before
evaluation. An observer blind to conditions analyzed images
for percent of cross-section that failed to exclude blue dye.
Evaluation of apoptosis. Rates of apoptosis at the 7-day
timepoint were assessed using the Klenow-FragEL DNA
fragmentation detection kit (Oncogene, Cambridge, Mas-
sachusetts) according to the manufacturer’s recommenda-
tions. Images of the processed slides (two per vessel to
minimize slide-to-slide variability) were acquired at high
resolution. An observer blind to conditions analyzed the
percent of total area that was positive for peroxidase staining
of DNA fragmentation for each slide using the ImagePro
Plus analysis suite.
Statistical analysis. All values are expressed as mean and
standard error for each treatment. Statistical significance for
these analyses was determined using one-factor analysis of
variance repeated measures, with significance determined at
95% (with Bonferroni, Tukey-A, Fisher PLSD, and
Student-Newman-Keuls performed where applicable in
SPSS 6.1 and Statview).
RESULTS
Catheter intensity. A US intensity field was generated
from a hydrophone scanning tank. Peak intensity is located
on the catheter surface at the center of the US transducer
and falls off radially as seen in Figure 1.
Gene delivery efficiencies. Blue fluorescent protein ex-
pression was used to measure gene delivery efficiency, with
results summarized in Figure 2. No statistically significant
differences in BFP expression were detected among the
plasmid, adenoviral and control groups without ultrasound
(p . 0.05). After US exposure, plasmid-mediated BFP
expression increased 12-fold over plasmid control (p ,
0.05), and adenoviral-mediated BFP expression increased
19-fold over adenoviral control (p , 0.05). Ultrasound also
increased BFP expression for plasmid relative to adenoviral
Abbreviations and Acronyms
Adv 5 adenovirus
BFP 5 blue fluorescent protein
CMV 5 cytomegalovirus
DNA 5 deoxyribonucleic acid
p 5 plasmid
PBS 5 phosphate buffered saline
US 5 ultrasound
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treatment alone (p , 0.025). Representative photographs
depicting these results are presented as Figure 3.
Cell viability. Nonviable cell area was evaluated on frozen
arterial cross-sections by trypan blue dye exclusion. Ultra-
sound did not increase cell death in the plasmid group
relative to the controls (p . 0.05). In the adenoviral group
US exposure significantly increased cell death relative to
adenoviral treatment alone (p , 0.012). All other compar-
isons were not significant (p . 0.05, Table 1).
Apoptosis rates. Apoptosis was evaluated with the
Klenow-FragEL DNA fragmentation detection kit (Onco-
gene, Cambridge, Massachusetts) to assess the impact of
apoptosis on the total population of nonviable cells. Ultra-
sound did not significantly increase apoptosis among con-
trol, plasmid and adenoviral groups (p . 0.05, Table 1).
Local macrophage infiltration. Cross-sectional macro-
phage content was evaluated via immunohistochemistry at
the 7-day timepoint. No statistically significant alterations
in macrophage infiltration occurred in any group (p . 0.05).
These results did not change after US exposure (p . 0.05,
Table 1).
DISCUSSION
Summary of results. This study shows that US exposure
after balloon angioplasty significantly enhances in vivo
plasmid-mediated BFP expression 12-fold over plasmid
controls and adenoviral-mediated BFP expression 19-fold
over adenoviral controls. Most interestingly, US increased
BFP expression for plasmid relative to adenoviral treatment
alone. Ultrasound enhancement of gene delivery resulted in
increased toxicity by only one criterion measured in the
present experiment (cell death rates for the adenoviral
group), with no significant alterations in apoptosis or
inflammation.
Catheter design and clinical application. For practical
application of localized cardiovascular gene therapy, the US
probe should be catheter-based, accessible to the human
arteries (especially coronary arteries) and should offer an
infusion port for gene delivery. A therapeutic ultrasound
catheter was designed to meet these requirements. The
settings for these experiments were determined from initial
pilot experiments examining toxicity and delivery efficiency
in vitro and in vivo.
Because restenosis represents a crucial clinical application
for which endovascular access is available, we evaluated
impact of US-mediated enhancement of gene delivery in a
rabbit model of arterial mechanical overdilation injury.
Because toxicity of gene delivery increases with dose for
either plasmid or adenovirus, we selected safer doses that
Figure 1. Ultrasound intensity field map for the EKOS catheter as measured in a hydrophone scanning tank. The peak intensity is located on the surface
at the center of the ultrasound transducer and falls off away from that point. The field is axisymmetric around the catheter.
Figure 2. Blue fluorescent protein (BFP) expression. Expression of BFP 7
days after delivery of buffer (PBS), plasmid expressing BFP (p/BFP), or
adenovirus expressing BFP (Adv/BFP), each either with ultrasound treat-
ment (black bars) or without (white bars). Values represent mean 6
standard error.
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would be subtherapeutic without US enhancement. Blue
fluorescent protein expression was used to monitor gene
delivery efficiency after femoral angioplasty, and plasmid- or
adenoviral-mediated gene delivery with or without endovas-
cular US and was compared to control (saline) treatment. As
expected, no statistically significant differences in BFP
expression occurred among plasmid, adenoviral and PBS
groups at these doses without US (p . 0.05). Prior work has
shown that 0.1 mM BFP molecules, approximately 105 cop-
ies per cell of 1 to 2 pl volume (15), are needed to surpass
detectable endogenous autofluorescence of a mammalian
cell. The delivery efficiencies of plasmid and low-dose
adenovirus, while not strictly zero, do not yield statistically
significant increases in signal intensity relative to these
sensitivity thresholds. The impact of US on these efficien-
cies was tremendous. After US exposure, plasmid-mediated
BFP expression increased 12-fold over plasmid control (p ,
0.05), and adenoviral-mediated BFP expression increased
19-fold over adenoviral control (p , 0.05). Given low
baseline plasmid and adenoviral-mediated gene delivery
Figure 3. Representative photomicrographs. Photomicrographs (203 magnification) depicting blue fluorescent protein (BFP) expression as fluorescence
through an FITC-HYQ filter with internal elastic lamina noted by yellow arrow after treatment with (A) saline alone, (B) saline with ultrasound (US), (C)
pBFP alone, (D) pBFP with US, (E) AdBFP alone or (F) AdBFP with US. Scale 5 20 mm.
Table 1. Macrophage Count, Apoptosis Evaluation and
Cell Death
Macrophages Apoptosis Cell Death
PBS 5.66 6 1.06 1.43 6 0.51 24.16 6 3.74
PBS-US 6.11 6 1.08 1.53 6 0.50 9.29 6 3.68
Adv/BFP 2.11 6 0.56 0.53 6 0.30 13.00 6 2.55
Adv/BFP-US 4.44 6 1.26 0.85 6 0.23 26.00 6 5.78
P/BFP 4.00 6 1.62 0.24 6 0.06 12.14 6 3.75
P/BFP-US 4.44 6 2.04 0.26 6 0.06 16.66 6 5.11
Macrophage infiltration, rates of apoptosis, and rates of total cell death 7 days after
delivery of buffer (PBS), plasmid expressing BFP (p/BFP) or adenovirus-expressing
BFP (Adv/BFP), each either with or without ultrasound (US) treatment. Macro-
phages represent total number of RAM-11 positive cells per cross-section. Apoptosis
is expressed as the percent of cross-section positive by fragel staining. Cell death is
expressed as the percent of cross-section that failed to exclude Evans Blue dye. Values
represent mean 6 standard error for each parameter.
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efficiencies at the doses employed here, it is promising that
high copy numbers per cell (at least 105) can be achieved
with in vivo US exposure. But the most interesting result is
that US increased BFP expression for plasmid relative to
adenoviral treatment alone (p , 0.025). Given the cost,
handling and safety advantages of plasmid-mediated gene
delivery, these results are particularly exciting. Although the
present study selected 16 min incubation total for gene
transfer, transducer design alone (i.e., to the length of
desired transfection) should allow reduction to a single
4-min increment to achieve the observed results. Dose-
response studies may offer still further enhancements with
accompanying reductions in transfection time.
Evaluation of cell toxicity. Above certain thresholds for
intensity and duration, US has been found to induce breaks
in DNA (16), apoptosis (17), membrane damage (7) and
enhanced free radical delivery (18). We thus quantitatively
evaluated cell viability, apoptosis and local infiltrate of
macrophages in each group as potentially limiting compli-
cations of the strategy in vivo. Nonviable cell area was
evaluated on frozen arterial cross-sections by trypan blue dye
exclusion, with the results presented in Table 1. As expected
from pilot experiments used to determine the US settings,
US did not increase cell death in the plasmid group relative
to the controls (p . 0.05). However, US exaggerated the
toxicity of low-dose adenovirus, possibly through additive
injury achieved by increased viral delivery (p , 0.012). All
other comparisons were not significant (p . 0.05).
Further, we quantitatively examined apoptosis on histo-
logic sections to assess contributions to the total population
of nonviable cells, with results compiled in Table 1. No
differences in rates of apoptosis occurred among control,
plasmid and adenoviral groups, and US exposure did not
significantly alter rates for any group in the present study
(p . 0.05 for all comparisons), suggesting that US-
facilitated changes in adenoviral-mediated cell viability may
be due largely to the cellular response to physical cell injury
in the presence of the viral vector. More importantly, these
results suggest that transgene expression observed at a given
timepoint may not be lost subsequently to already predes-
tined cell death, although future experiments must confirm
these effects.
Previous work has demonstrated that adenoviral gene
delivery at doses substantially higher than those employed
here induces a vigorous local inflammatory response (4)
relative to low-dose strategies (19). Because macrophages
play a crucial role in atherogenesis and constitute the
predominant inflammatory cell type in acute inflammation
within 48 h (20), we directly evaluated local macrophage
infiltration as a potential limitation of the present strategy.
As depicted in Table 1, no statistically significant alterations
in macrophage infiltration occurred in any group in the
present work (p . 0.05). These results did not change after
US exposure (p . 0.05). In this experiment, US enhance-
ment of gene delivery resulted in increased cell death only in
the viral group, with no significant alterations in apoptosis
or inflammation in the other groups.
Conclusions. Gene therapy is expected to alter manage-
ment of vascular diseases but requires improvement of gene
delivery before successful clinical applications can be real-
ized. As concerns regarding safety of viral-mediated gene
transfer have been reinforced by recent adverse events in
clinical trials, the present strategy of local delivery and US
enhancement may allow therapeutic levels to be achieved at
safer viral doses. More interestingly, these results demon-
strate that US can increase the efficiency of safer nonviral
platforms for arterial delivery to levels previously attained
only by adenoviral strategies. Future characterization of
these promising effects must be undertaken to confirm that
therapeutic doses can be achieved through this strategy
without any additive long-term limitations. After appropri-
ate dose-response and toxicity studies, evaluation of putative
therapeutic transgenes may be more safely undertaken with
these strategies. This technique may also be used to target
gene therapy to any organ or lesion accessible to this
catheter-based device.
Reprint requests and correspondence: Dr. Michael D. Dake,
Department of Cardiovascular and Interventional Radiology,
Stanford University Medical Center, Room H-3647, Stanford,
California 94305. E-mail: mddake@stanford.edu.
REFERENCES
1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas
AM, Pajak A. Myocardial infarction and coronary deaths in the World
Health Organization MONICA Project. Registration procedures,
event rates, and case-fatality rates in 38 populations from 21 countries
in four continents. Circulation 1994;90:583–612.
2. Clesham JG. Gene therapy made difficult. Heart 1998;80:313–4.
3. Shneider MD, French BA. The advent of adenovirus: gene therapy for
cardiovascular disease. Circulation 1993;88:1937–42.
4. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene
transfer into normal rabbit arteries results in prolonged vascular cell
activation, inflammation, and neointimal hyperplasia. J Clin Invest
1995;96:2955–65.
5. Takeshita S, Gal D, Leclerc G, et al. Increased gene expression after
liposome mediated arterial gene transfer associated with intimal
smooth muscle cell proliferation. J Clin Invest 1994;93:652–61.
6. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated
vascular endothelial growth factor gene transfer to human coronary
arteries after angioplasty. Hum Gene Ther 2000;11:263–70.
7. Miller MW, Miller DL, Brayman AA. A review of in vitro bioeffects
of inertial ultrasonic cavitation from a mechanistic perspective. Ultra-
sound Med Biol 1996;22:1131–54.
8. Feichheimer M, Boylan JF, Parker S, Sisken JE, Patel GL, Zimmer
SG. Transfection loading of mammalian cells with plasmid DNA by
scrape loading and sonication loading. Proc Natl Acad Sci USA
1987;84:8463–7.
9. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME.
Ultrasound-mediated transfection of mammalian cells. Hum Genet
Ther 1996;7:1939–46.
10. Greenleaf WJ, Bolander ME, Sarkar G, Goldring MB, Greenleaf JF.
Artificial cavitation nuclei significantly enhance acoustically induced
cell transfection. Ultrasound Med Biol 1998;24:587–95.
11. Unger EC, McCreery TP, Sweitzer RH. Ultrasound enhances gene
expression of liposomal transfection. Invest Radiol 1997;32:723–7.
12. Lawrie A, Brisken AF, Francis SE, et al. Ultrasound enhances reporter
1979JACC Vol. 37, No. 7, 2001 Amabile et al.
June 1, 2001:1975–80 Gene Delivery Via Therapeutic Ultrasound
gene expression after transfection of vascular cells in vitro. Circulation
1999;99:2617–20.
13. Mukherjee D, Wong J, Griffin B, et al. Ten-fold augmentation of
endothelial uptake of vascular endothelial growth factor with ultra-
sound after systemic administration. J Am Coll Cardiol 2000;35:
1678–86.
14. Shohet RV, Chen S, Zhou VT, et al. Echocardiographic destruction of
albumin microbubbles directs gene delivery to the myocardium.
Circulation 2000;101:2554–6.
15. Tsien RY. The green fluorescent protein. Ann Rev Biochem 1998;67:
509–44.
16. Miller DL, Thomas RM, Frazier ME. Ultrasonic cavitation indirectly
induces strand breaks in DNA of viable cells in vitro by the action of
residual hydrogen peroxide. Ultrasound Med Biol 1991;17:729–35.
17. Ashush H, Rozenszajin LA, Blass M, et al. Apoptosis induction of
human myeloid leukemic cells by ultrasound exposure. Cancer Res
2000;60:1014–20.
18. Kondo T, Kano E. Effect of free radicals induced by ultrasonic
cavitation on cell killing. Int J Radiat Biol 1988;54:475–86.
19. Waugh JM, Li-Hawkins J, Yuksel E, et al. Thrombomodulin over-
expression to limit neointima formation. Circulation 2000;102:332–7.
20. Inflammation and repair. In: Cotran RS, editor. Robbins Pathologic
Basis of Disease. 5th ed. Philadelphia, PA: W.B. Saunders Company,
1994:76.
1980 Amabile et al. JACC Vol. 37, No. 7, 2001
Gene Delivery Via Therapeutic Ultrasound June 1, 2001:1975–80
